leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 05:07:50 - browse：83771

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

knowledge

WSS

ASCO: AstraZeneca says CAR

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Covid vaccine financial winners and losers, from Pfizer to Novavax

States should stop sabotaging methadone treatment reform

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Cord blood banking comes at a high cost to babies

focus

leisure time

explore

At least 13 dead in Texas as scorching temps continue

Patient advocates debate FDA's accelerated approval process

How one medical school became remarkably diverse

Woman returns to dialysis after doctors remove transplanted pig kidney

Moonlake's readout produced a cash windfall. Risks remain

There's no autism epidemic. It's an autism diagnosis epidemic

Malaria cases in Florida and Texas: Here’s what you need to know

Ionis drug prevents swelling attacks due to hereditary angioedema

Hepatitis C has a cure — but many Americans still lack access to it

FDA's Pazdur wants cancer trials to range beyond China alone

explore

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

With trial win, GSK could get blood cancer drug back on market

Study says nonprofit hospitals fall short in charity care spending

Washington mulls new rules to avert another Change Healthcare

Ultragenyx gene therapy for rare liver ailment succeeds in late

Abortion pill case raises question: who can sue the FDA?

entertainment

hotspot

knowledge

entertainment